Novo Nordisk A/S Stock Performance
Novo Nordisk A/S shares are trading at $40.00, reflecting a modest 3.24% gain over the past month but significant weakness over longer time horizons, per SID market data. The stock has declined 16.86% over the trailing three months and 24.80% over the past year, underscoring sustained selling pressure in the GLP-1 leader. NVO currently trades below both its 50-day moving average of $41.35 and its 200-day moving average of $44.28, indicating a technically bearish posture. The 14-day relative strength index sits at 54.0, placing the stock in neutral territory and suggesting neither overbought nor oversold conditions. Average daily volume stands at approximately 16.69 million shares, according to Massive/Polygon data. The stock's beta of 0.352 reflects significantly lower volatility relative to the broader market, consistent with its positioning within the defensive healthcare sector. The current market capitalization is approximately $223.5 billion.
Novo Nordisk A/S Valuation Analysis
Novo Nordisk trades at a price-to-earnings ratio of 12.76, which represents a notable discount to many large-cap healthcare peers, per SID market data. The PEG ratio stands at 2.05, suggesting the stock's earnings multiple remains elevated relative to its projected growth rate, according to SEC filings and consensus estimates. The price-to-book ratio of 8.43 reflects the market's continued premium for Novo Nordisk's intangible assets, brand strength, and dominant franchise in GLP-1 receptor agonist therapies. The company offers a dividend yield of 3.66%, which is above the healthcare sector median and provides a meaningful income component for shareholders. The combination of a sub-13 P/E with a dividend yield exceeding 3.5% indicates the stock has re-rated meaningfully lower following its 24.8% decline over the past twelve months. These valuation metrics position Novo Nordisk as a higher-yielding name within the large-cap pharmaceutical space.
Smart Money Activity for NVO
Novo Nordisk's composite smart money score stands at 52 out of 100, generating a neutral signal, per SID market data. Institutional positioning represents the strongest component, scoring 23.0 out of 25, indicating robust ownership and sustained interest from large fund managers as reported in 13F institutional filings. Insider activity scores 12.5 out of 25, reflecting a moderate level of transactions by company executives and directors according to SEC Form 4 filings. The congressional trading component registers at 10.4 out of 25, suggesting limited but present activity among U.S. legislators holding or trading NVO shares. Dark pool activity scores just 6.5 out of 25, the weakest component, indicating relatively low levels of off-exchange block trading in recent periods. The divergence between high institutional conviction and subdued dark pool activity suggests that while large asset managers maintain significant positions, there has been limited incremental accumulation through non-displayed venues. The overall neutral reading implies no decisive directional bias from sophisticated market participants at current price levels.
Novo Nordisk A/S Earnings Outlook
Novo Nordisk faces a series of upcoming earnings reports beginning on August 21, 2026, with consensus analyst estimates projecting earnings of $0.81 per share for each of the next four reporting periods, according to analyst estimates compiled by SID. The uniform $0.81 estimate across all quarters suggests analysts currently model steady-state earnings with limited sequential variability. No actual results have been reported yet for these periods, leaving the surprise trajectory undetermined. In prior cycles, Novo Nordisk has benefited from accelerating Wegovy and Ozempic revenues, though the current consensus implies expectations for more stable, predictable earnings generation. The company's trailing P/E of 12.76 against the $0.81 quarterly estimate annualizes to approximately $3.24 per share, per company earnings reports. Investors will closely monitor the August 21 report for commentary on GLP-1 supply chain expansion, competitive dynamics, and pricing trends across key geographies.
Wall Street Analyst Ratings for NVO
Recent Wall Street coverage of Novo Nordisk reflects a mixed but incrementally constructive consensus, per SID consensus data. In the most recent round of ratings dated September 22-23, 2026, three firms maintain bullish stances while two hold neutral positions. Rothschild & Co Redburn reiterated a Buy rating, joined by DNB Carnegie which also maintained its Buy recommendation, according to Wall Street analyst reports. Banco Santander continued its Outperform rating, adding to the bullish contingent. On the neutral side, Jyske Bank reiterated its Hold rating, and TD Cowen also maintained a Hold stance. Notably, none of the five most recent ratings reflected any change from prior recommendations, suggesting analyst conviction levels have stabilized following the stock's 24.8% decline over the past year. The absence of downgrades despite significant price deterioration indicates that analysts view the current valuation as appropriately discounting near-term headwinds. The 3-to-2 ratio of bullish-to-neutral ratings suggests cautious optimism among the covering analyst community.
